MediSieve's device captures Leukaemia blasts from the bloodstream in order to reduce the patient's white blood cell count.

Leukaemia is a cancer of the bone marrow where white blood cells (WBC) are produced. When a person has Leukaemia, the bone marrow produces a lot of abnormal and immature WBCs, or “blasts”, which multiply rapidly and are incapable of contributing to immune function.

These eventually spill over into the bloodstream crowding out normal cells. High levels of circulating Leukaemia blasts present problems for both chemotherapy and newer targeted monoclonal antibody therapies. The circulating cells can prevent the therapeutics from reaching the bone marrow where the disease begins and the death of large numbers of circulating cells can create potentially life-threatening side effects for the patient.

Significant worldwide burden

176k affected annually
1 death every 9 minutes

High morbidity and mortality

Mortality rate 35%

Stroke

Fatigue

Pneumonia

Heavy burden of patient care

Draining Chemotherapies

Constant blood tranfusions

long patient care

The long-term goal for clinical trials is to prove the value of magnetic filtration as a pre-treatment to traditional or next generation Leukaemia therapies. The MediSieve technology would only remove the blasts and would bring a patient's WBC count down to normal levels, reducing the side-effects of a further chemotherapy.

Latest News

Job Posting: Regulatory Affairs Manager

Job Posting: Regulatory Affairs Manager
November 25, 2020

Job Title: Regulatory Affairs Manager Reports to : CTO  Start Date : ASAP  Hours of Work : Full-time Salary : £50-60k PA  Closing Date : December 2020 (or earlier if a suitable candidate is found)  Please send your  CV and a cover letter  explaining what you can...
Job Posting: Product Development Scientist

Job Posting: Product Development Scientist
November 12, 2020

Job Title: Product Development Scientist Reports to : CTO  Start Date : ASAP  Hours of Work : Full-time Salary : £37.5 - 45k PA  Closing Date : December 2020 (or earlier if a suitable candidate is found)  Please send your  CV and a cover letter  explaining what ...